|
1
|
Specht L: Prognostic factors in Hodgkin's
disease. Dan Med Bull. 39:409–422. 1992.
|
|
2
|
Josting A: Prognostic factors in Hodgkin
lymphoma. Expert Rev Hematol. 3:583–592. 2010. View Article : Google Scholar
|
|
3
|
Specht L and Nissen NI: Prognostic
significance of tumor burden in Hodgkin's disease PS I and II.
Scand J Haematol. 36:367–375. 1986. View Article : Google Scholar
|
|
4
|
Specht L: Tumor burden as the main
indicator of prognosis in Hodgkin's disease. Eur J Cancer.
28:1982–1985. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gobbi PG, Ghirardelli ML, Solcia M, Di
Giulio G, Merli F, Tavecchia L, Bertè R, Davini O, Levis A, Broglia
C, et al: Image-aided estimate of tumor burden in Hodgkin's
disease: evidence of its primary prognostic importance. J Clin
Oncol. 19:1388–1394. 2001.PubMed/NCBI
|
|
6
|
Gobbi PG, Broglia C, Di Giulio G, Mantelli
M, Anselmo P, Merli F, Zinzani PL, Rossi G, Callea V, Iannitto E,
et al: The clinical value of tumor burden at diagnosis in Hodgkin
lymphoma. Cancer. 101:1824–1834. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gobbi PG, Valentino F, Bassi E, Coriani C,
Merli F, Bonfante V, Marchianò A, Gallamini A, Bolis S, Stelitano
C, et al: Chemoresistance as a function of the pretherapy tumor
burden and the chemotherapy regimen administered: differences
observed with two current chemotherapy regimens for advanced
Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 5:396–402. 2011.
View Article : Google Scholar
|
|
8
|
Gobbi PG, Broglia C, Merli F, Dell’Olio M,
Stelitano C, Iannitto E, Federico M, Bertè R, Luisi D, Molica S,
Cavalli C, Dezza L and Ascari E: Vinblastine, bleomycin and
methotrexate chemotherapy plus irradiation for patients with
early-stage, favorable Hodgkin's lymphoma: the experience of the
Gruppo Italiano Studio Linfomi (GISL). Cancer. 98:2393–2401. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iannitto E, Minardi V, Gobbi PG, Calvaruso
G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L,
Stelitano C, et al: Response-guided ABVD chemotherapy plus
involved-field radiation therapy for intermediate-stage Hodgkin
lymphoma in the pre-positron emission tomography era: a Gruppo
Italiano Studio Linfomi (GISL) prospective trial. Clin Lymphoma
Myeloma. 9:138–144. 2009. View Article : Google Scholar
|
|
10
|
Gobbi PG, Levis A, Chisesi T, Broglia C,
Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, et
al: ABVD versus modified Stanford V versus MOPPEBVCAD with optional
and limited radiotherapy in intermediate- and advanced-stage
Hodgkin's lymphoma: final results of a multicenter randomized trial
by the Intergruppo Italiano Linfomi. J Clin Oncol. 23:9198–9207.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Federico M, Luminari S, Iannitto E,
Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F,
Stelitano C, Pozzi S, et al: ABVD compared with BEACOPP compared
with CEC for the initial treatment of patients with advanced
Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo
Studio dei Linfomi Trial. J Clin Oncol. 27:805–811. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lister TA, Crowther D, Sutcliffe SB,
Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA and
Tubiana M: Report of a committee convened to discuss the evaluation
and staging of patients with Hodgkin's disease: Cotswolds meeting.
J Clin Oncol. 7:1630–1636. 1989.PubMed/NCBI
|
|
13
|
Hasenclever D and Diehl V: A prognostic
score for advanced Hodgkin's disease. International Prognostic
Factors Project on Advanced Hodgkin's Disease. N Engl J Med.
339:1506–1514. 1998. View Article : Google Scholar
|
|
14
|
Vassilakopoulos TP, Angelopoulou MK,
Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A,
Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, et al:
Prognostic factors in advanced stage Hodgkin’s lymphoma: the
significance of the number of involved anatomic sites. Eur J
Haematol. 67:279–288. 2001.
|
|
15
|
Wickramasinghe SN: Human Bone Marrow.
Blackwell Scientific Publications; Oxford: pp. 211–216. 1976
|
|
16
|
Devine BJ: Gentamicin therapy. Drug Intell
Clin Pharm. 8:650–655. 1974.
|
|
17
|
Armitage P and Berry G: Statistical
Methods in Medical Research. 2nd edition. Blackwell Scientific
Publication; Oxford: pp. 369–396. 1987
|
